Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: J Pharmacol Exp Ther. 2004 Jun 22;311(2):485–491. doi: 10.1124/jpet.104.069658

Fig. 5.

Fig. 5

Pharmacological inhibition of PARP (for 2 months) improves ESPVR (Emax), PRSW, +dP/dt-EDV, EDPVR, and efficiency in advanced aging-associated heart failure. Overall values of Emax, PRSW, dP/dt-EDV, EDPV relationships, and efficiency. Values as mean ± S.E.M. of 6 to 10 experiments in each group. *, P < 0.05 versus young adult; #, P < 0.05 versus aging.